Ideal cardiovascular health is inversely associated with non-alcoholic fatty liver disease: a prospective analysis
Non-alcoholic fatty liver disease (NAFLD) is one of the most important causes of liver diseases worldwide with a global prevalence currently estimated to be 24% and will probably emerge as the leading cause of end-stage liver disease in the coming decades.1-3 In addition to progression into nonalcoholic steatohepatitis (NASH), cirrhosis, and liver carcinoma,4 NAFLD has also been proved to be independently associated with cardiovascular disease, chronic kidney disease, type 2 diabetes, neoplasms, and other extrahepatic diseases.
TYPE 2 diabetes sufferers are advised to eat healthily in order to control the condition, but everyone deserves a treat every now and then. Burgers are generally considered an unhealthy food, but if you have diabetes and love a burger, this is the type you should opt for.
Histologic evaluation of focal liver disease and mass lesions can be challenging. In a pediatric population, inadequate sampling or unclear diagnosis can lead to repeat biopsies that require general anesthesia. Adding non-lesional liver tissue (NLT) or transitional liver tissue (TLT) to standard biopsy procedures may aid pathologists in reaching a diagnosis. We aim to evaluate the safety, outcomes, and utility of adding NLT/TLT to evaluate pediatric liver lesions.
To develop a model to estimate drug dose delivered to the liver following transarterial chemoembolization (TACE) with radiopaque drug-eluting beads (RO DEB) based on bead density and cone-beam computed tomography (CBCT) in a woodchuck hepatoma model.
Caffeic acid (CA) is a natural phytochemical with lethal effects against hepatocellular carcinoma in vitro. However, efficacy requires high locoregional concentrations. Currently available porous hydrogel beads are derivatized with sulfonic acid groups and at neutral pH these negatively charged groups provide binding sites for the cationic drug doxorubicin. A loading protocol was developed for these drug-eluting beads to retain and release neutralized CA for embolic delivery. Pharmacokinetic analysis in an animal model compared loaded beads to an alternative embolic delivery method.
The generation of patient derived xenografts (PDXs) from core needle biopsies of intermediate and advanced stage HCC patients who are not candidates for resection is technically challenging due to the small quantities of tumor tissue obtained. Further complicating PDX generation is the high rate of EBV infection in humans (>90%) and the presence of EBV-transformed B lymphocytes in HCC samples, which grow opportunistically in immunocompromised mice to yield EBV-associated lymphomas at the expense of HCC xenografts.
The purpose of these studies was to determine which percutaneous device yielded the best samples for staging of liver disease based on the standard criteria for adequate biopsy.
As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterized as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death; it is associated with extrahepatic manifestations such as chronic kidney disease cardiovascular disease and sleep apnea.
As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterised as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death. NAFLD is also associated with extrahepatic manifestations such as chronic kidney disease, cardiovascular disease and sleep apnoea.
There is mounting evidence that besides increasing risk of cirrhosis, end stage liver disease and hepatocellular carcinoma, non alcoholic fatty liver disease (NAFLD) also affects risk of disease in organs beyond the liver. For example, NAFLD is an independent risk factor for cardiovascular disease, type 2 diabetes and chronic kidney disease, and NAFLD also increases risk of cardiac arrhythmias and aortic valve disease . However, whether NAFLD is a risk factor for impaired myocardial function is uncertain.In a study of 308 asymptomatic subjects recruited from attendees at a Health Promotion Centre in a Univer...
Abstract Non-alcoholic fatty liver disease (NAFLD) is one of the most common comorbidities associated with overweight and metabolic syndrome (MetS). Importantly, NAFLD is one of its most dangerous complications because it can lead to severe liver pathologies, including fibrosis, cirrhosis and hepatic cellular carcinoma. Given the increasing worldwide prevalence of obesity, NAFLD has become the most common cause of chronic liver disease and therefore is a major global health problem. Currently, NAFLD is predominantly regarded as a hepatic manifestation of MetS. However, accumulating evidence indicates that the effe...
More News: Alcoholism | Cancer & Oncology | Carcinoma | Cardiology | Cardiovascular | Chronic Kidney Disease | Cirrhosis | Diabetes | Diabetes Type 2 | Endocrinology | Fatty Liver Disease (FLD) | General Medicine | Heart | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Men | Non-alcoholic Fatty Liver Diseases (NAFLD) | Study | Urology & Nephrology